Insightec has now treated 10,000 patients across Europe, the Middle East, and Africa using its Exablate Neuro platform, an incisionless therapy that applies MR-guided focused ultrasound to address essential tremor and Parkinson’s disease. The company confirmed the milestone alongside data showing treatment volumes in the region doubled within the past three years.
That acceleration points to a broader shift in how patients access care for movement disorders. Many individuals once faced a narrow set of options, primarily medication or invasive brain surgery. Focused ultrasound now presents a third route, delivered through 62 treatment centers spanning 20 countries in the EMEA region. Globally, the footprint extends much further, with more than 30,000 patients treated at 226 sites.
Jake Ghannam, Insightec’s Executive Vice President and Chief Commercial Officer, framed the number in human terms. He described patients regaining the ability to hold a coffee cup, sign a card, or embrace a grandchild without shaking. Ghannam also credited the clinical teams who adopted the technology early and integrated it into standard treatment pathways.
For Juan José, a 56-year-old carpenter in Spain who has lived with essential tremor since childhood, the treatment changed daily life. He avoided public settings for years, worried that others noticed his hands shaking whenever he lifted a glass or used a fork. After completing treatment on both sides, he reported a renewed sense of control and confidence.
Yet significant obstacles remain. Despite the regionwide growth, access remains inconsistent. A patient’s location can still determine whether focused ultrasound is a realistic option. Some countries offer established care pathways and reimbursement support, while others lag behind.
Insightec Chairman and CEO Maurice Ferré acknowledged that disparity. He argued that geographic location should not dictate treatment access and described the company’s next goal as building more equitable systems rather than simply chasing larger patient counts. The company continues working with health authorities, clinical societies, and patient organizations to strengthen access where it remains limited.
